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Abstract
Background: Interleukin (IL)-16 is a T cell chemoattractant produced by peripheral mononuclear cells. We
investigated whether IL-16 plays a pro- or an anti-inflammatory role in antineutrophil cytoplasmic antibody-
associated vasculitis (AAV). Furthermore, we investigated whether the level of IL-16 could predict the activity and
extent of organ damage in AAV based on AAV-specific indices.
Methods: Seventy-eight patients with AAV from a prospective observational cohort were included in this analysis.
Blood sampling and clinical assessments, including the Birmingham Vasculitis Activity Score (BVAS), Five-Factor
Score (FFS), Short Form 36-item Health Survey (SF-36), and Vasculitis Damage Index (VDI), were performed, and
laboratory data were collected. Serum IL-16 was measured from stored sera.
Results: The median age was 62.0 years, and 27 patients were male. The median serum IL-16 concentration was
84.1 pg/dL, and the median BVAS, FFS, VDI, and SF-36 scores were 7.0, 1.0, 3.0, and 48.0, respectively. Among the
AAV-related indices, the serum IL-16 concentration was correlated with VDI (R2 = 0.306, P = 0.006), but not with
BVAS (R2 = 0.024, P = 0.834), FFS (R2 = − 0.069, P = 0.550), or SF-36 (R2 = − 0.015, P = 0.898). The serum IL-16
concentration also did not correlate with either the erythrocyte sedimentation rate or the C-reactive protein
concentration. Per our analysis based on organ involvement, only patients with ear, nose, and throat manifestations
had higher serum IL-16 concentrations relative to those with other conditions (P = 0.030).
Conclusions: This was the first study to elucidate the clinical implication of serum IL-16 in patients with AAV. We
found that the serum IL-16 level may reflect the cross-sectional VDI scores among AAV-specific indices. Future
studies with larger numbers of patients and serial measurements could provide more reliable data on the clinical
implications of serum IL-16 in AAV.
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Background
Antineutrophil cytoplasmic antibody (ANCA)-associated
vasculitis (AAV) refers to a group of systemic vasculit-
ides that affect small vessels, including microscopic poly-
angiitis (MPA), granulomatosis with polyangiitis (GPA),
and eosinophilic granulomatosis with polyangiitis
(EGPA) [1, 2]. In clinical practice, the following are often
assessed at every visit: Birmingham Vasculitis Activity
Score (BVAS), version 3 for activity; Five-Factor Score
(FFS) for prognosis; the Korean version of the Short
Form 36-item Health Survey (SF-36) for functional sta-
tus; and the Vasculitis Damage Index (VDI) for end
organ damage [3–6]. Although a single serum biomarker
cannot replace each AAV-specific index, such a marker
may have clinical implications as an immediate and con-
venient indicator if it reflects a specific AAV-related
index. Therefore, the identification of a serologic bio-
marker that can estimate a cross-section of the many
AAV-specific indices would be useful.
Interleukin (IL)-16 was first introduced as a T cell
chemoattractant produced by peripheral mononuclear
cells in 1982 [7]. This cytokine is produced by various
cells, such as CD4+ T cells, CD8+ T cells, mast cells,
eosinophils, and fibroblasts [8]. Bioactive IL-16 in-
duces the chemotaxis of CD4+ TH1 cells by binding
to CD4 to enhance T cell proliferation and stimulate B cell
development, while inhibiting antigen-triggered TH2 cell-
mediated inflammation and impairing macrophage inflam-
matory protein (MIP)-1beta and stromal cell-derived factor
(SDF)-1alpha-mediated T cell chemoattraction [9]. Previous
reports have highlighted the clinical significance of serum
IL-16 in several typical systemic autoimmune diseases.
Serum IL-16 was observed to be significantly elevated
in patients with systemic lupus erythematosus (SLE)
relative to healthy controls, and the level of this cytokine
was correlated with SLE activity [10]. Unlike SLE, the
clinical role of serum IL-16 remains controversial in
rheumatoid arthritis (RA). It was suggested that IL-16
production may be accelerated by IL-17 in RA and that
serum IL-16 correlated with disease activity reflecting
pro-inflammatory effect [11, 12]. However, there was a
report that treatment with exogenous IL-16 inhibits the
production of pro-inflammatory cytokines in rheumatoid
synovitis, demonstrating the anti-inflammatory effects of
IL-16 [13].
Because SLE, RA, and AAV share inflammatory mecha-
nisms, we aimed to investigate whether serum IL-16 plays
a pro- or an anti-inflammatory role in AAV. Furthermore,
we wondered whether serum IL-16 might reflect the in-
flammatory burden of small pro-inflammatory molecules
or reflect a consequence of extensive tissue damage. How-
ever, no previous study has elucidated the clinical implica-
tion of serum IL-16 in patients with AAV. In this study,
we measured the serum IL-16 levels in patients with AAV
and investigated the association of this factor with the
cross-sectional scores of AAV-specific indices, such as the
BVAS, FFS, SF-36, and VDI.
Methods
Patients
We included 78 patients with AAV in this study. The
patients were enrolled in the Severance Hospital ANCA-
associated VasculitidEs (SHAVE) cohort, a prospective
observational cohort of patients with MPA, GPA, and
EGPA, from November 2016 to May 2019. All patients
were newly diagnosed with AAV at the Division of
Rheumatology, Department of Internal Medicine, Yonsei
University College of Medicine and Severance Hospital.
The patients met the criteria of the 2007 European
Medicine Agency algorithms for AAV and polyarteritis
nodosa (the 2007 EMA algorithm) and the 2012 revised
International Chapel Hill Consensus Conference No-
menclature of Vasculitides [1, 2]. At the time of diagno-
sis, patients with serious infections, including hepatitis B
or C virus infection, malignancies, or secondary vascu-
litis features related to autoimmune diseases, were ex-
cluded from the SHAVE cohort. In addition, all patients
were immunosuppressant-naïve at the enrollment of this
study. This study was approved by the Institutional Re-
view Board of Severance Hospital (4-2016-0901), and
written informed consent was obtained from the patients
at the time of blood sampling.
Clinical and laboratory data
The collected demographic data included age and sex.
The clinical manifestations were counted based on the
items in BVAS version 3. We obtained the following la-
boratory data at diagnosis: perinuclear (P)-ANCA, cyto-
plasmic (C)-ANCA, myeloperoxidase (MPO)-ANCA,
proteinase 3 (PR3)-ANCA, and acute-phase reactants,
including erythrocyte sedimentation rate (ESR) and C-
reactive protein (CRP). We also collected AAV-specific
indices such as the BVAS version 3, FFS, SF-36, and
VDI scores on the same day as the blood sampling and
clinical assessment. According to the SHAVE cohort
protocol, we obtained whole blood from each consenting
patient, immediately isolated sera, and stored the samples
at − 80 °C. Serum IL-16 concentrations in stored sera were
measured using ELISA kits (Abcam, Cambridge, UK)
according to the manufacturer’s instructions.
Statistical analyses
All statistical analyses were conducted using SPSS soft-
ware (version 25 for Windows; IBM Corp., Armonk, NY,
USA). Continuous variables are expressed as means with
standard deviations, and categorical variables are
expressed as numbers (percentages). The correlation co-
efficient between the two variables was obtained using a
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Spearman correlation analysis. Significant differences in
continuous variables between the two groups were com-
pared using the Mann–Whitney test. P values < 0.05
were considered statistically significant.
Results
Characteristics of AAV patients
The baseline characteristics of the patients are described
in Table 1. The median age was 62.0 years, and 27 pa-
tients were men. The median BVAS, FFS, and VDI
scores were 7.0, 1.0, and 3.0, respectively.
MPO-ANCA and PR3-ANCA were detected in 43 and
7 patients, respectively. The most common clinical
manifestation was pulmonary (64.1%), followed by renal
and ear, nose, and throat (ENT) manifestations. The me-
dian ESR and CRP levels were 37.5mm/h and 2.6mg/L,
respectively. The median serum IL-16 level was 84.1 pg/
mL.
Correlation analysis
Of the AAV-specific indices, the serum IL-16 concentra-
tion correlated with the cross-sectional VDI scores (R2 =
0.306, P = 0.006), but not with the BVAS, FFS, or SF-36
scores or with ESR or CRP (Table 2).
Comparative analysis
We compared the serum IL-16 concentration according
to each organ or system wherein the involvement fre-
quency exceeded 25%. Among the general, ENT, pul-
monary, and renal manifestations, only patients with
ENT manifestations exhibited a higher serum IL-16 con-
centration than those without ENT manifestations (P =
0.030; Table 3). In a correlation analysis of the serum
IL-16 concentration and the total weighted score per
each organ or system involvement, the former was cor-
related with only the total weighted score of ENT mani-
festations (R2 = 0.279, P = 0.013).
Also, we compared the serum IL-16 concentration ac-
cording to the ANCA status and specific disease type.
IL-16 was significantly higher in patients with PR3-
ANCA than those with MPO-ANCA or those without
ANCA (P < 0.001; Table 4). IL-16 was higher in patients
with GPA than those with MPA or EGPA although sta-
tistically not significant.
Discussion
In this study, we demonstrated a correlation of the
serum IL-16 concentration with cross-sectional VDI
scores, but not with other AAV-specific indices. In
addition, the serum IL-16 concentration differed signifi-
cantly between patients with ENT manifestations and
those without.
This study has raised many questions. For example,
why does the serum IL-16 level correlate with only the
cross-sectional VDI scores? The first hypothesis is that
serum IL-16 might be associated with fibrotic changes.
Compared to BVAS, FFS, or acute-phase reactants, the
VDI of AAV may be more strongly associated with
chronic inflammation (late phase or fibrotic phase) than
with acute inflammation (early phase or pro-fibrotic
phase) [14]. Kazuo et al. reported that IL-16 levels




Age (years) 62.0 (21.0)









SF-36 PCS score 48.0 (36.2)
SF-36 MCS score 57.0 (34.5)
ANCA positivity (N (%))
MPO-ANCA positivity 43 (55.1)
PR3-ANCA positivity 7 (9.0)
ANCA negativity 28 (35.9)
Clinical manifestations (N (%))
General 27 (34.6)
Cutaneous 9 (11.5)
Mucous membrane and eye 5 (6.4)





Nervous system 17 (21.8)
Acute-phase reactants
ESR (mm/h) 37.5 (44.0)
CRP (mg/L) 2.6 (14.6)
IL-16 (pg/mL) 84.1 (198.7)
Values are expressed as medians (interquartile ranges, IQR) or
numbers (percentages)
AAV ANCA-associated vasculitis, ANCA antineutrophil cytoplasmic antibody,
MPA microscopic polyangiitis, GPA granulomatosis with polyangiitis, EGPA
eosinophilic granulomatosis with polyangiitis, BVAS Birmingham Vasculitis
Activity Score, FFS Five-Factor Score, VDI Vasculitis Damage Index, SF-36 Short
Form-36, P perinuclear, C cytoplasmic, MPO myeloperoxidase, PR-3 proteinase
3, AST aspartate aminotransferase, ALT alanine aminotransferase, ESR
erythrocyte sedimentation rate, CRP C-reactive protein
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correlated with skin involvement in patients with sys-
temic sclerosis reflecting the role of IL-16 in skin fibrosis
[15]. Furthermore, there was a study showing that pro-
fibrotic mediators induce IL-16 upregulation and IL-16
gene expression was elevated in lung tissue from patient
with idiopathic pulmonary fibrosis [16]. Therefore, we
assume that the positive correlation between serum IL-
16 and VDI may reflect the extent of end organ damage
due to progressive fibrosis.
The second hypothesis is that serum IL-16 might be
associated with the secondary necrosis of neutrophils.
Considering the importance of neutrophil in pathogen-
esis of AAV, we focused on the relation between IL-16
and neutrophil. It was previously revealed that in neu-
trophils, IL-16 was stored in a preformed form and that
it was passively released during secondary necrosis ra-
ther than being actively released from viable or apoptotic
cells [17]. Under normal circumstances, neutrophils have
a short lifespan and are cleared via apoptosis once their
function has ended. However, apoptotic neutrophils may
not be properly cleared in chronic inflammatory situa-
tions, and secondary necrosis may occur. We assumed
that in late-phase AAV, accumulated neutrophils
undergo secondary necrosis and secrete IL-16, which
causes tissue damage. This process may explain the posi-
tive correlation between serum IL-16 and VDI of AAV.
The association between ENT involvement and serum
IL-16 may be secondary to the phase difference between
acute inflammation (early phase or pro-fibrotic phase)
and chronic inflammation (late phase or fibrotic phase).
We therefore analyzed the sub-items of four frequent
manifestations per phase. Regarding the general manifes-
tations, all sub-items such as myalgia, arthralgia, fever,
and weight loss may be closely related to the acute
phase. Regarding the pulmonary manifestations, five of
seven sub-items may be somewhat related to the acute
phase. Likewise, regarding the renal manifestations, four
of five sub-items may also be related to acute inflamma-
tion or exacerbation. Conversely, with respect to ENT
manifestations, four of five sub-items, such as paranasal
sinusitis (thickened sinus wall), subglottic stenosis, con-
ductive hearing loss, and sensorineural hearing loss, tend
to be related to the relatively chronic phase of AAV [3].
However, there is a possibility that the degree of in-
flammatory burden of renal and lung involvement in our
patient population was not very high. Despite 50.0% and
64.1% of our patients had renal and pulmonary involve-
ment, our patient’s median BVAS was 7.0, implying that
the inflammation of renal and pulmonary manifestation
was not highly active. This could partly be the factor
that serum IL-16 correlating only with ENT involve-
ment. Further research with larger population is needed
to clarify the relationship between serum-IL-16 and
organ involvement.
Another hypothesis regarding the association of
serum-IL16 with ENT involvement is that IL-16 might
have an association with PR3-ANCA. PR3-ANCA tends
to have dominant ENT involvement and is associated
Table 2 Correlation analysis of serum IL-16 with continuous
variables in 78 patients with AAV
Variables Correlation coefficient (r2) P value
AAV-specific indices
BVAS 0.024 0.834
FFS − 0.069 0.550
VDI 0.306 0.006
SF-36 PCS score − 0.015 0.898
SF-36 MCS score − 0.122 0.288
Acute phase reactants
ESR (mm/h) − 0.034 0.769
CRP (mg/L) − 0.007 0.952
AAV ANCA-associated vasculitis, ANCA antineutrophil cytoplasmic antibody,
BVAS Birmingham Vasculitis Activity Score, FFS Five-Factor Score, VDI Vasculitis
Damage Index, SF-36 Short Form-36, AST aspartate aminotransferase, ALT
alanine aminotransferase, ESR erythrocyte sedimentation rate, CRP
C-reactive protein
Table 3 Mean serum IL-16 levels based on organ or system
involvement (frequency ≥ 25%) in AAV
Involved organ system Absence Presence P value
General 167.4 ± 188.5 124.2 ± 137.6 0.297
Ear, nose, and throat 112.3 ± 142.5 199.2 ± 194.5 0.030
Pulmonary 147.0 ± 130.3 155.4 ± 194.0 0.839
Renal 151.0 ± 151.9 153.8 ± 193.7 0.945
Values are expressed as medians (interquartile ranges, IQR) or
numbers (percentages)
AAV ANCA-associated vasculitis, ANCA antineutrophil cytoplasmic antibody,
MPA microscopic polyangiitis, GPA granulomatosis with polyangiitis, EGPA
eosinophilic granulomatosis with polyangiitis, BVAS Birmingham Vasculitis
Activity Score, FFS Five-Factor Score, VDI Vasculitis Damage Index, SF-36 Short
Form-36, P perinuclear, C cytoplasmic, MPO myeloperoxidase, PR-3 proteinase
3, AST aspartate aminotransferase, ALT alanine aminotransferase, ESR
erythrocyte sedimentation rate, CRP C-reactive protein
Table 4 Mean serum IL-16 levels based on disease type and
ANCA status
Variables Serum IL-16 P value
Disease type
MPA 128.3 ± 151.2 0.162
GPA 213.9 ± 224.2
EGPA 133.1 ± 136.0
ANCA status
MPO-ANCA positivity 133.1 ± 143.3 < 0.001
PR3-ANCA positivity 408.1 ± 275.0
ANCA negativity 133.1 ± 143.3
ANCA antineutrophil cytoplasmic antibody, MPA microscopic polyangiitis, GPA
granulomatosis with polyangiitis, EGPA eosinophilic granulomatosis with
polyangiitis, MPO myeloperoxidase, PR3 proteinase 3
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more with the GPA than MPA or EGPA. Serum IL-16
in our study was significantly higher in patients with PR3-
ANCA. One possible explanation for this phenomenon is
that IL-16 could play a role in causing granuloma. There
was a report showing that high levels of IL-16 were seen
in immunohistochemical staining of sarcoidosis granu-
loma [18]. Regarding that the PR3-ANCA is more relevant
in GPA than in MPA, there is a possibility of IL-16 being
associated with granuloma. However, further research is
needed to understand the relationship between serum IL-
16 and PR3-ANCA.
One strength of this study is that it is the first to dem-
onstrate an association of serum IL-16 with cross-
sectional VDI scores, but not with BVAS or FFS scores
or acute -phase reactants. Furthermore, we excluded pa-
tients with other underlying serious medical conditions,
and IL-16 was measured from the stored sera which was
drawn before starting immunosuppressant drugs, which
can minimize the confounding factors. However, our
study also has several limitations. First, the sample size
was not large enough to ensure that the findings are
generalizable to all patients with AAV. Second, we can-
not provide serial or paired results, despite the inclusion
of patients with AAV in the prospective cohort. Third,
we could not assess the duration from symptom to diag-
nosis, which might be informative to evaluate the acute
or chronic status due to the complexity of the disease.
Conclusions
In conclusion, the serum IL-16 level may reflect the
cross-sectional VDI scores among AAV-specific indices.
Future studies with larger numbers of patients and serial
measurements could provide more reliable data on the
clinical implications of serum IL-16 in AAV.
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